The present invention provides methods of detecting breast cancer or breast cancer cells comprising: (a) obtaining a liquid sample from a subject which sample comprises cells, microvesicles and/or exosomes; and (b) determining the presence of soluble or cell surface associated Cyr61 in the sample; wherein the liquid sample is selected from blood, and/or bone marrow aspirate and wherein the determination of the presence of Cyr61 comprises detection via ELISA.

The present invention provides methods of detecting breast cancer or breast cancer cells comprising: (a) obtaining a liquid sample from a subject which sample comprises cells, microvesicles and/or exosomes; and (b) determining the presence of soluble or cell surface associated Cyr61 in the sample; wherein the liquid sample is selected from blood, and/or bone marrow aspirate and wherein the determination of the presence of Cyr61 comprises detection via ELISA.

The present disclosure belongs to the field of tumor diagnosis, and specifically relates to a biomarker panel, a microfluidic device and a detection kit for capturing circulating tumor cells. The biomarker panel includes a first biomarker and a second biomarker; wherein: the first biomarker is EPCAM; the second biomarker is one or a combination of two or more of CD9, CD41, THBS1, RGS18, and RGS10; the circulating tumor cells are pancreatic cancer circulating tumor cells and/or breast cancer circulating tumor cells. In the present disclosure, by using antibodies against novel surface biomarkers of pancreatic cancer or breast cancer circulating tumor cells (CTCs), the enrichment and detection rate of CTCs in the blood of patients are significantly improved, and the possibility of missed detection is effectively reduced; meanwhile, the capture and enrichment efficiency of CTCs are enhanced, thus providing strong support for dynamic tumor monitoring, prognostic evaluation and personalized precise treatment of cancer patients, and offering broad market value and application prospects.

This disclosure provides methods and compositions for detecting splice variants of the endoglin protein, enabling the accurate diagnosis of cancer. Additionally, the use of endoglin-specific antibodies enhances the detection process, offering a more precise and reliable approach to identifying cancer-related variants of endoglin.

Acute exposure to estrogenic chemicals is shown herein to induce DNA damage mediated by formation of ER-dependent R-loops. Disclosed herein are methods for evaluating the safety and activity of a xenoestrogen. Also disclosed are methods for identifying subject particularly susceptible to the genotoxic effects of endogenous estrogens or environmental xenoestrogens. This method can be used to select suitable hormone therapies, such as a selective estrogen receptor modulator (SERM), aromatase inhibitor, or selective estrogen receptor degrader (SERD).

Provided is a method of determining whether a patient has bladder cancer, colon cancer, or breast cancer. Also provided is a method of determining whether a patient has a chronic inflammatory disease. Additionally provided is a method of evaluating patient response to a treatment for a chronic inflammatory disease. Further provided is a method of developing a treatment for a chronic inflammatory disease in a patient.

The present disclosure provides methods, device, assemblies, and systems for dispensing and visualizing single cells. For example, provided herein are systems and methods for dispensing a dispense volume into a plurality of wells of a multi-well device, where, on average, a pre-determined number of cells (e.g., 1-20) are present in the dispense volume, and determining, via a cellular label, the number of cells present in each of the plurality of wells. Such dispensing and cell detection may be repeated a number of times with respect to wells identified as having less than the pre-determined number of cells in order increase the number wells in the multi-well device containing the desired number (e.g., a single cell).

The present disclosure provides methods, device, assemblies, and systems for dispensing and visualizing single cells. For example, provided herein are systems and methods for dispensing a dispense volume into a plurality of wells of a multi-well device, where, on average, a pre-determined number of cells (e.g., 1-20) are present in the dispense volume, and determining, via a cellular label, the number of cells present in each of the plurality of wells. Such dispensing and cell detection may be repeated a number of times with respect to wells identified as having less than the pre-determined number of cells in order increase the number wells in the multi-well device containing the desired number (e.g., a single cell).